Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Nabriva Therapeutics
Nabriva Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Pharmaceutical
Nabriva Therapeutics appoints Will Sargent as Vice President of Commercial Strategy and Investor Relations
He will lead development of commercial strategy for the launch of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP)
Research & Development
Elyse Seltzer joins Nabriva Therapeutics as Chief Medical Officer
Dr William Prince moves to Senior Vice President, Clinical Science
Infection Control
Nabriva Therapeutics secures financing of up to US$120m
To advance development of antibiotics for the treatment of infections caused by resistant gram-positive and gram-negative bacteria
Pharmaceutical
Nabriva Therapeutics strengthens board and management team
Charles Rowland and Dr Steven Gelone join the company
Research & Development
Nabriva Therapeutics hires Colin Broom as CEO
Also establishes new US subsidiary in the Philadelphia area
Subscribe now